Acquired by Novartis in Sep 2024
MOR - MorphoSys AG
NASDAQ
->
Healthcare
->
Biotechnology
Planegg,
Germany
Type: Equity
MOR price evolution
MOR
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $131.26 | $158.5 | $187.84 | $184.33 |
| Short term investments | ||||
| Net receivables | $30.83 | $38.87 | $58.36 | $86.18 |
| Inventory | $62.07 | $70.53 | $71.73 | |
| Total current assets | $675.01 | $814.02 | $797.98 | $862.87 |
| Long term investments | ||||
| Property, plant & equipment | $10.95 | $14.99 | $45.35 | $47.55 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $1831.53 | $2026.31 | $2100.98 | $2142.5 |
| Current liabilities | ||||
| Accounts payable | $72.59 | $109.8 | $116.96 | $119.82 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $487.84 | $264.31 | $254.22 | $241.7 |
| Long term debt | $255.23 | $252.82 | $277.73 | $275.94 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $2093.2 | $1977.26 | $2167.95 | $2110.83 |
| Shareholders' equity | ||||
| Retained earnings | -$1328.1 | -$1013.13 | -$1061.41 | -$941.81 |
| Other shareholder equity | $102.93 | $88.44 | $118.84 | $99.37 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $158.5 | $402.35 | $123.25 | $109.79 |
| Short term investments | $861.54 | $692.58 | ||
| Net receivables | $42.65 | $112.35 | $85.79 | $89.84 |
| Inventory | $62.07 | $24.25 | $20.76 | $9.96 |
| Total current assets | $814.02 | $1089.04 | $1132.97 | $1206.82 |
| Long term investments | $196.59 | |||
| Property, plant & equipment | $14.99 | $50.99 | $49.59 | $50.74 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $517.12 | |||
| Total investments | ||||
| Total assets | $2026.31 | $2396.93 | $2556.25 | $1659.51 |
| Current liabilities | ||||
| Accounts payable | $28.39 | $38.58 | $73.79 | $47.56 |
| Deferred revenue | ||||
| Short long term debt | $0.42 | $0.42 | ||
| Total current liabilities | $264.31 | $278.35 | $284.54 | $200.46 |
| Long term debt | $252.82 | $329.87 | $322.13 | $272.76 |
| Total noncurrent liabilities | $956.94 | |||
| Total debt | ||||
| Total liabilities | $1977.26 | $2239.52 | $2311.38 | $1038.19 |
| Shareholders' equity | ||||
| Retained earnings | -$1013.13 | -$823.41 | -$672.35 | -$157.89 |
| Other shareholder equity | $88.44 | $115.33 | $52.76 | $2.21 |
| Total shareholder equity | $244.88 | $621.32 | ||
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $27.54 | |||
| Cost of revenue | ||||
| Gross Profit | $24.72 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $288.72 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$1.58 | |||
| Interest expense | $3.71 | |||
| Net income | ||||
| Net income | -$314.96 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $238.28 | $278.27 | $327.7 | |
| Cost of revenue | $9.17 | |||
| Gross Profit | $187.32 | $229.65 | $318.52 | |
| Operating activities | ||||
| Research & development | $125.4 | |||
| Selling, general & administrative | $159.15 | |||
| Total operating expenses | $420.23 | $442.1 | $293.72 | |
| Operating income | $33.98 | |||
| Income from continuing operations | ||||
| EBIT | $33.98 | |||
| Income tax expense | -$1.19 | $168.58 | -$75.4 | |
| Interest expense | -$91.99 | -$142.44 | -$28.35 | |
| Net income | ||||
| Net income | -$189.73 | -$151.06 | $97.89 | |
| Income (for common shares) | $97.89 | |||
| (in millions $) | 1 May 2024 | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $41 | $15.37 | $72.5 | $33.13 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $3.5 | $43 | -$51.21 | -$50 |
| Effect of exchange rate | $1.88 | -$6.39 | $0.03 | -$3.95 |
| Change in cash and equivalents | -$27.24 | -$243.85 | -$214.52 | -$218.02 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $97.89 | |||
| Operating activities | ||||
| Depreciation | $8.25 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $35.27 | |||
| Investing activities | ||||
| Capital expenditures | -$4.46 | |||
| Investments | -$830.12 | |||
| Total cash flows from investing | $15.37 | $345 | -$831.01 | -$879.62 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | $317.93 | |||
| Total cash flows from financing | $43 | $311.42 | $1322.92 | $907.19 |
| Effect of exchange rate | -$6.39 | -$10.61 | $2.99 | $3.4 |
| Change in cash and equivalents | -$243.85 | $279.1 | $13.45 | $65.48 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 151.04M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -55.81% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.87 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.38 |
| Quick ratio | N/A |